# PolyPid Ltd. (PYPD)

Source: https://www.quantisnow.com/company/PYPD
Generated: 2026-11-09T23:17:15.978Z

- Ticker: PYPD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2020
- SEC CIK: 0001611842
- Website: polypid.com

## About

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

## Latest PYPD news and filings

- 2026-10-29 12:00 UTC [Earnings Date] [PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026](https://www.quantisnow.com/insight/polypid-to-report-third-quarter-2026-financial-results-and-operational-6762585)
- 2026-10-28 12:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6760623)
- 2026-10-28 12:00 UTC [PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections](https://www.quantisnow.com/insight/polypid-unveils-expanded-pipeline-strategy-introducing-pd01b-a-new-kynatrix-6760551)
- 2026-10-27 10:42 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on PolyPid Ltd. with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-polypid-ltd-with-a-new-price-6758342)
- 2026-10-21 12:00 UTC [PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026](https://www.quantisnow.com/insight/polypid-to-present-d-plex-microbiology-data-at-idweek-2026-6752943)
- 2026-10-15 12:30 UTC [PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026](https://www.quantisnow.com/insight/polypid-to-host-virtual-investor-day-on-wednesday-october-28-6747396)
- 2026-10-01 13:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6731825)
- 2026-10-01 13:15 UTC [European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀](https://www.quantisnow.com/insight/european-medicines-agency-validates-polypids-marketing-authorization-application-for-d-plex-6731802)
- 2026-10-01 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6731764)
- 2026-10-01 12:56 UTC [PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities](https://www.quantisnow.com/insight/polypid-regains-european-commercialization-rights-for-d-plex-expanding-global-commercialization-6731697)
- 2026-09-15 12:30 UTC [Conference Announcement] [PolyPid Announces Participation in Upcoming Fall Investor Conferences](https://www.quantisnow.com/insight/polypid-announces-participation-in-upcoming-fall-investor-conferences-6715508)
- 2026-08-12 20:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6678418)
- 2026-08-12 20:01 UTC [SEC Form S-8] [SEC Form S-8 filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-polypid-ltd-6677692)
- 2026-08-12 11:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6677019)
- 2026-08-12 11:30 UTC [Earnings Date] [PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/polypid-provides-corporate-update-and-reports-second-quarter-2026-financial-6676991)
- 2026-07-30 12:00 UTC [Earnings Date] [PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026](https://www.quantisnow.com/insight/polypid-to-report-second-quarter-2026-financial-results-and-operational-6655119)
- 2026-07-29 12:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6652917)
- 2026-07-29 12:30 UTC [PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀](https://www.quantisnow.com/insight/polypid-announces-fda-acceptance-of-nda-with-priority-review-for-6652886)
- 2026-07-21 11:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6643196)
- 2026-07-21 11:30 UTC [PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada](https://www.quantisnow.com/insight/polypid-announces-exclusive-partnership-with-azurity-pharmaceuticals-for-the-commercialization-6643183)
- 2026-07-17 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer - US Warshavsky Ori](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer---us-6640996)
- 2026-07-17 20:04 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Missulawin Jonathan](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-missulawin-jonathan-6640957)
- 2026-07-17 20:04 UTC [SEC Form 4] [SEC Form 4 filed by Deputy CEO, EVP, RD, CRA Hazan Dalit Fellous](https://www.quantisnow.com/insight/sec-form-4-filed-by-deputy-ceo-evp-rd-cra-6640956)
- 2026-07-17 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Barenholz Yechezkel](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-barenholz-yechezkel-6640953)
- 2026-07-17 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Stein Robert Benjamin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stein-robert-benjamin-6640951)
- 2026-07-17 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Dror-Darwish Nir](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dror-darwish-nir-6640943)
- 2026-07-17 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Benamram Joseph](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-benamram-joseph-6640940)
- 2026-07-17 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Krinsky Itzhak](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-krinsky-itzhak-6640934)
- 2026-07-17 20:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Story Brooke](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-story-brooke-6640933)
- 2026-07-17 20:01 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Akselbrad Dikla Czaczkes](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-akselbrad-dikla-6640913)
- 2026-07-15 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6638190)
- 2026-06-10 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6596957)
- 2026-06-01 12:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6580850)
- 2026-06-01 12:30 UTC [PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀](https://www.quantisnow.com/insight/polypid-completes-new-drug-application-submission-to-fda-for-d-plex-6580815)
- 2026-05-20 12:30 UTC [Conference Announcement] [PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference](https://www.quantisnow.com/insight/polypid-to-participate-in-the-craig-hallum-23rd-annual-institutional-investor-6564427)
- 2026-05-13 11:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by PolyPid Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-polypid-ltd-6549695)
- 2026-05-13 11:30 UTC [Earnings Date] [PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://www.quantisnow.com/insight/polypid-provides-corporate-update-and-reports-first-quarter-2026-financial-6549658)
- 2026-05-06 12:00 UTC [Earnings Date] [PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026](https://www.quantisnow.com/insight/polypid-to-report-first-quarter-2026-financial-results-and-operational-6534179)
- 2026-04-28 12:30 UTC [PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting](https://www.quantisnow.com/insight/polypid-to-present-data-from-shield-ii-phase-3-trial-6517861)
- 2026-04-13 13:15 UTC [PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026](https://www.quantisnow.com/insight/polypid-to-present-new-phase-3-shield-ii-data-demonstrating-6497498)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PYPD
- Earnings history: https://www.quantisnow.com/earnings/PYPD
- Dividend history: https://www.quantisnow.com/dividends/PYPD
- Insider transactions: https://www.quantisnow.com/insiders/PYPD
- Options chain: https://www.quantisnow.com/options/PYPD
- SEC 8-K filings only: https://www.quantisnow.com/company/PYPD/8-k
- RSS and alerts for PYPD: https://www.quantisnow.com/docs/rss-feeds.md